Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…

As SARS-CoV-2 continues to mutate we demonstrate the performance of 

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…

Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…

Antibiotic resistance is increasing globally and represents one of the biggest public health challenges of our time. In the US alone, there are more than 2.8 million cases of…

Why are haptens such a hard-to-solve target class for antibody development? Small molecules are ubiquitous in our environment. They cover hormones and toxins to drugs and vitamins. There is an…

Researchers at the National Cancer Institute (Centro di Referimento Oncologico IRCCS), Aviano, Italy, have published a new paper in Analytical and Bioanalytical Chemistry. Using aptamers from Aptamer…

In the recently published paper in Talenta from Dr Mark Platt and the team at Loughborough University, they demonstrate a novel approach for aptamer biosensors to detect…